The market's 91% implied probability against a hantavirus vaccine in 2026 reflects the absence of any candidate that has advanced beyond preclinical stages or early Phase 1 trials. Researchers report no Phase 3 data, with DNA and mRNA approaches still limited to animal models or small human immunogenicity studies that require additional dosing regimens. Sporadic case patterns and limited commercial incentives have slowed funding, while regulatory pathways demand extensive efficacy evidence that remains years away absent an accelerated program comparable to Operation Warp Speed. New model updates or trial initiations could narrow uncertainty by late 2026, but current epidemiological surveillance shows no shift in development timelines.